Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06855329 · ClinicalTrials.gov registry record
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
A clinical trial of Interstitial Lung Disease and Progressive Pulmonary Fibrosis, sponsored by University of Massachusetts, Worcester.
- Recruiting
- Registry status
- 500
- Enrollment target
- 13
- Study locations
NCT06855329: Recruiting study of Interstitial Lung Disease and Progressive Pulmonary Fibrosis, sponsored by University of Massachusetts, Worcester.
NCT06855329 is a study of Interstitial Lung Disease and Progressive Pulmonary Fibrosis that is actively recruiting participants, run by University of Massachusetts, Worcester. The registered enrollment target is 500 participants, below the 553-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (10% lower). The trial reports 13 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06855329, a study of Interstitial Lung Disease and Progressive Pulmonary Fibrosis, is actively recruiting participants, sponsored by University of Massachusetts, Worcester.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over time, and 2) Determine whether multi-dimensional PPF prediction outperforms component approaches.
Primary Outcome
TFS is defined as the time from the 12-month pulmonary function tests to death or lung transplant. Censoring will occur at 12-months or earlier if lost to follow-up.
Conditions Studied
Study Locations (13)
Massachusetts
- University of Massachusetts Chan Medical School - Worcester
Michigan
- University of Michigan - Ann Arbor
Texas
- University of Texas Southwestern - Dallas
Virginia
- University of Virginia - Charlottesville
Washington
- University of Washington - Seattle
New South Wales
- Royal Prince Alfred Hospital - Camperdown
Queensland
- Prince Charles Hospital - Brisbane
Victoria
- Austin Health - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2029-12 |
What NCT06855329 shows while recruiting
NCT06855329 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 553-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (10% lower).
The record links to 2 conditions, with Interstitial Lung Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06855329 lists 13 locations in 13 states (Massachusetts, Michigan, Texas).
Frequently Asked Questions
What is clinical trial NCT06855329 about?
NCT06855329 is a clinical study titled "PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis". This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis...
What is the current status of trial NCT06855329?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-05-01. Estimated completion is 2029-12.
What conditions does trial NCT06855329 study?
This clinical trial studies the following conditions: Interstitial Lung Disease, Progressive Pulmonary Fibrosis.
Who is sponsoring clinical trial NCT06855329?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06855329 being conducted?
This trial has 13 study locations across Massachusetts, Michigan, Texas, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06855329's enrollment target sits among peer trials
500 8th of 36 higher than 29 of 36 other Interstitial Lung Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Interstitial Lung Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
RECRUITING · Phase 2
-
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
RECRUITING · Phase 3
-
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
RECRUITING
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI